The FDA has approved an ophthalmic bevacizumab treatment for wet age-related macular degeneration, a decision that gives formal regulatory clearance to a drug that has been widely used in eye care for years. According to the report, the approval was issued on July 24 and marks the first FDA-approved ophthalmic bevacizumab for wet AMD.
The move is significant because bevacizumab has been a common treatment in American retina clinics for about two decades, despite not previously having an FDA-approved formulation specifically for that eye condition. In other words, a therapy that was already familiar to many specialists is now entering a new phase with official approval for wet macular degeneration.
For patients, the change means there is now an eye-specific bevacizumab option with formal FDA backing for wet AMD. That could help bring more clarity around how the drug is labeled and presented in treatment discussions, replacing a long period in which its use for this purpose depended on off-label prescribing.
The approval does not introduce bevacizumab to retina care for the first time; instead, it recognizes and formalizes a treatment approach that clinics have relied on for years. After a long stretch of off-label use, bevacizumab now has a clearer regulatory status in the treatment of wet age-related macular degeneration.
